FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W51067300> ?p ?o ?g. }

• W51067300 endingPage "6" @default.
• W51067300 startingPage "53" @default.
• W51067300 abstract "This article discusses some of the issues raised by development of a new low-dose oral contraceptive (OC) now available in the US after 12 years of clinical use around the world. The principle of using as little of a therapeutic agent as possible to achieve the desired results is the rationale for low-dose OCs. It is very difficult to show a correlation of ambiguous side effects such as depression and mood changes and the dosage level. Some controversy accompanies efforts to reduce grave adverse reactions to OCs, primarily cardiovascular, by lowering the dose: doubts about the underlying epidemiological data result from the probable process of self-selection among women choosing OCs and changing prescription practices by physicians as well as the steady decline in frequency of serious cardiovascular problems, both of which create a shifting baseline. Thrombophlebitis has an even more ambiguous correlation: epidemiologists using clinical and hospital diagnostic records were apparently unaware of the considerable evidence which began to appear in the late 1950s on the unreliability of the clinical diagnosis of deep vein thrombosis. Mechanisms that may be involved in initiating cardiovascular accidents must be considered in the effort to demonstrate the beneficial effects of dosage reduction in a nonepidemiological manner. Little support remains for the notion that coagulation factor changes are important in the genesis of cardiovascular problems attributed to OCs, and the Framingham study, which is attempting to relate information on lipid factors predisposing to myocardial infarction to use of OCs, has not had a single myocardial infarction in a premenopausal woman. The role of lipoproteins among older OC users who smoke cannot however be dismissed and possible risk factors should be minimized even in the absence of detailed information. Other issues discussed are the apparent difference between metabolic transformation of the inactive isomer removed from norgestrel and the metabolism of the active compound, the near impossibility of detecting very small differences in contraceptive effectiveness, the importance of cycle control in determining acceptance of an OC, and the question of whether important beneficial side effects will persist as dosages are lowered." @default.
• W51067300 created "2016-06-24" @default.
• W51067300 creator A5025066695 @default.
• W51067300 date "1983-01-01" @default.
• W51067300 modified "2023-09-23" @default.
• W51067300 title "Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol." @default.
• W51067300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6403700" @default.
• W51067300 hasPublicationYear "1983" @default.
• W51067300 type Work @default.
• W51067300 sameAs 51067300 @default.
• W51067300 citedByCount "2" @default.
• W51067300 countsByYear W510673002015 @default.
• W51067300 crossrefType "journal-article" @default.
• W51067300 hasAuthorship W51067300A5025066695 @default.
• W51067300 hasConcept C107130276 @default.
• W51067300 hasConcept C126322002 @default.
• W51067300 hasConcept C177713679 @default.
• W51067300 hasConcept C197934379 @default.
• W51067300 hasConcept C2777902738 @default.
• W51067300 hasConcept C2779076696 @default.
• W51067300 hasConcept C2780186607 @default.
• W51067300 hasConcept C2908647359 @default.
• W51067300 hasConcept C2986817661 @default.
• W51067300 hasConcept C500558357 @default.
• W51067300 hasConcept C71924100 @default.
• W51067300 hasConcept C99454951 @default.
• W51067300 hasConceptScore W51067300C107130276 @default.
• W51067300 hasConceptScore W51067300C126322002 @default.
• W51067300 hasConceptScore W51067300C177713679 @default.
• W51067300 hasConceptScore W51067300C197934379 @default.
• W51067300 hasConceptScore W51067300C2777902738 @default.
• W51067300 hasConceptScore W51067300C2779076696 @default.
• W51067300 hasConceptScore W51067300C2780186607 @default.
• W51067300 hasConceptScore W51067300C2908647359 @default.
• W51067300 hasConceptScore W51067300C2986817661 @default.
• W51067300 hasConceptScore W51067300C500558357 @default.
• W51067300 hasConceptScore W51067300C71924100 @default.
• W51067300 hasConceptScore W51067300C99454951 @default.
• W51067300 hasIssue "1 Suppl" @default.
• W51067300 hasLocation W510673001 @default.
• W51067300 hasOpenAccess W51067300 @default.
• W51067300 hasPrimaryLocation W510673001 @default.
• W51067300 hasRelatedWork W2026435239 @default.
• W51067300 hasRelatedWork W2042048935 @default.
• W51067300 hasRelatedWork W2121456671 @default.
• W51067300 hasRelatedWork W2272084611 @default.
• W51067300 hasRelatedWork W2367140913 @default.
• W51067300 hasRelatedWork W2737252977 @default.
• W51067300 hasRelatedWork W2899084033 @default.
• W51067300 hasRelatedWork W3189109043 @default.
• W51067300 hasRelatedWork W4242983638 @default.
• W51067300 hasRelatedWork W4255572155 @default.
• W51067300 hasVolume "28" @default.
• W51067300 isParatext "false" @default.
• W51067300 isRetracted "false" @default.
• W51067300 magId "51067300" @default.
• W51067300 workType "article" @default.